While Dr Tillett is the right person to respond, he is spot on. You don't attend that conference unless you want to get out of it something, meaning some serious talk with big pharma reps. RAC is NOT ready this year to do that, we need clinical results, the more the merrier to convince big pharma that they should take us seriously and we have scientific proof for that, not empty talk and assumptions and hopes. I would love if we would be in the position, but we are not there. Next year, especially is the stage 1 trial finishes and the results are outstanding, yes, it will make sense. Until then the only thing can happen that one big pharma might be interested to a regional deal. I am just being realistic.
RAC Price at posting:
$1.44 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)